{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:53:16Z","timestamp":1762080796249,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jns.2022.120526","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:47:20Z","timestamp":1671274040000},"page":"120526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Permanent non-progressive cinnarizine and flunarizine-induced parkinsonism: An under-recognized tardive syndrome in the elderly?"],"prefix":"10.1016","volume":"444","author":[{"given":"Stefano","family":"Calzetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Negrotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2022.120526_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","article-title":"For the EUROPARKINSON study group, prevalence of parkinsonism and Parkinson\u2019s disease in Europe: the EUROPARKINSON collaborative study. European Community concerted action on the epidemiology of Parkinson\u2019s disease","volume":"62","author":"De Rijk","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2022.120526_bb0010","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.52.6.1214","article-title":"Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976\u20131990","volume":"53","author":"Bower","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120526_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"Shin","year":"2012","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jns.2022.120526_bb0020","doi-asserted-by":"crossref","unstructured":"A.M.B. Dy, L.L.G. Limjoco, R.D.G. Jamora, Trimetazidine-induced parkinsonism: a systematic review, Front. Neurol. doi:https:\/\/doi.org\/10.3389\/fneur.2020.00044.","DOI":"10.3389\/fneur.2020.00044"},{"issue":"3","key":"10.1016\/j.jns.2022.120526_bb0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics. Incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.jns.2022.120526_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11598540-000000000-00000","article-title":"Drug-induced parkinsonism in the elderly. Incidence, management and prevention","volume":"29","author":"L\u03ccpez-Send\u03ccn","year":"2012","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.jns.2022.120526_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2022.120526_bb0040","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, a drug that displays partial agonism and functional selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jns.2022.120526_bb0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/medicines8060024","article-title":"Recognition and management of antipsychotic-induced parkinsonism in older adults: a narrative review","volume":"8","author":"Wisidagama","year":"2021","journal-title":"Medicines"},{"issue":"12","key":"10.1016\/j.jns.2022.120526_bb0050","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: a review of 17 years\u2019 experience in a regional pharmacovigilance center in France","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00004647-199703000-00009","article-title":"Quantification of neuroreceptors in the living human brain. III. D2-like dopamine receptors: theory validation and change during normal aging","volume":"17","author":"Wong","year":"1997","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jns.2022.120526_bb0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-016-2181-3","article-title":"Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study","volume":"73","author":"Lin","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2022.120526_bb0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.43.3_Part_1.552","article-title":"Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study","volume":"43","author":"Burn","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120526_bb0070","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.2005.073999","article-title":"Cardiac 123I-MIBG scintigraphy in patients with drug-induced parkinsonism","volume":"77","author":"Lee","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2022.120526_bb0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.archger.2012.05.001","article-title":"Combined use of 123I-metaiodobenzylguanidine (MIBG) and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced parkinsonism (DIP): a 2-year follow-up study","volume":"56","author":"Kim","year":"2013","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.jns.2022.120526_bb0080","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/jcbfm.1995.63","article-title":"D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study","volume":"15","author":"Brucke","year":"1995","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"3","key":"10.1016\/j.jns.2022.120526_bb0085","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1148\/radiol.2015151466","article-title":"Drug-induced parkinsonism versus idiopathic parkinson disease: utility of nigrosome 1 with 3-T imaging","volume":"279","author":"Sung","year":"2016","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.jns.2022.120526_bb0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/mdc3.12281","article-title":"Substantia nigra echogen\u0227icity predicts response to drug withdrawal in suspected drug-induced parkinsonism","volume":"3","author":"L\u03ccpez-Send\u03ccn Moreno","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.jns.2022.120526_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.parkreldis.2017.10.011","article-title":"Transcranial sonographic findings may predict prognosis of gastroprokinetic drug-induced parkinsonism","volume":"46","author":"Oh","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0100","article-title":"Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced parkinsonism","volume":"8","author":"Aamodt","year":"2022","journal-title":"npj Parkinson\u2019s Dis."},{"key":"10.1016\/j.jns.2022.120526_bb0105","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0140-6736(84)91516-2","article-title":"Drug-induced parkinsonism in the elderly","author":"Stephen","year":"1984","journal-title":"Lancet II"},{"key":"10.1016\/j.jns.2022.120526_bb0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0140-6736(87)90141-3","article-title":"Prognosis of drug-induced Parkinson\u2019s disease","author":"Wilson","year":"1987","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jns.2022.120526_bb0115","first-page":"215","article-title":"Drug-induced Parkinson\u2019s disease. A clinical review","volume":"18","author":"Bohlega","year":"2013","journal-title":"Neurosciences"},{"key":"10.1016\/j.jns.2022.120526_bb0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/mds.870130313","article-title":"Cinnarizine-induced parkinsonism: ten years later","volume":"13","author":"Mart\u00ed-Mass\u03cc","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0125","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4065\/73.8.724","article-title":"Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted county, Minnesota","volume":"73","author":"Chabolla","year":"1998","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.jns.2022.120526_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247354","article-title":"Drug-induced parkinsonism: a strong predictor of idiopathic Parkinson\u2019s disease","volume":"16","author":"Jeong","year":"2021","journal-title":"PLoS One"},{"issue":"Suppl. 7","key":"10.1016\/j.jns.2022.120526_bb0135","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1002\/mds.10575","article-title":"DAT imaging in drug-induced and psychogenic parkinsonism","volume":"18","author":"Tolosa","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0140","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/WNL.0b013e31826e25ce","article-title":"Past exposure to neuroleptic drugs and risk of Parkinson's disease in an elderly cohort","volume":"79","author":"Foubert-Samier","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120526_bb0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1517\/14740338.2013.787065","article-title":"Drug-induced parkinsonism","volume":"12","author":"L\u03ccpez-Send\u03ccn","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jns.2022.120526_bb0150","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.parkreldis.2014.05.011","article-title":"Differentiating drug-induced parkinsonism from Parkinson\u2019s disease. An update on non-motor symptoms and investigation","volume":"20","author":"Brigo","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2022.120526_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/mds.26209","article-title":"Parkinsonism following neuroleptic exposure: a double-hit hypothesis?","volume":"30","author":"Erro","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","article-title":"Tardive syndromes","volume":"389","author":"Savitt","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2022.120526_bb0165","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.parkreldis.2018.11.025","article-title":"Setting the record straight: the nosology of tardive syndromes","volume":"59","author":"Truong","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mds.870120119","article-title":"A long-term follow-up of cinnarizine- and flunarizine-induced parkinsonism","volume":"12","author":"Negrotti","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1353-8020(98)00032-7","article-title":"Calcium channel blocker-induced parkinsonism: clinical features and comparison with Parkinson\u2019s disease","volume":"4","author":"Garcia-Ruiz","year":"1998","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0180","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3233\/JPD-140414","article-title":"Iatrogenic parkinsonism:the role of flunarizine and cinnarizine","volume":"4","author":"Miguel","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2022.120526_bb0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.parkreldis.2020.06.023","article-title":"Expanding phenomenologic heterogeneity of tardive syndromes: time for an updated assessment tool","volume":"77","author":"Bhidayasiri","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2022.120526_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000003059","article-title":"Incident parkinsonism in older adults without Parkinson disease","volume":"87","author":"Buchman","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120526_bb0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00259-009-1289-4","article-title":"Clinical features and 123 I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson\u2019s disease","volume":"37","author":"Diaz-Corrales","year":"2010","journal-title":"Eur. J. Med. Mol. Imag."},{"key":"10.1016\/j.jns.2022.120526_bb0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2018.04.037","article-title":"DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice","volume":"53","author":"Yomtoob","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2022.120526_bb0205","first-page":"27","article-title":"The possible role of an active metabolite derived from the neuroleptic agent haloperidol in drug-induced parkinsonism","volume":"17","author":"Igarashi","year":"1998","journal-title":"J. Toxicol."},{"key":"10.1016\/j.jns.2022.120526_bb0210","doi-asserted-by":"crossref","unstructured":"C. Burkhardt, J.P. Kelly, Y.H. Lim, C.M. Filley, W.D. Parker Jr., Neuroleptic medications inhibit complex I of the electron transport chain, Ann. Neurol. 33 (1993) 512\u2013517.","DOI":"10.1002\/ana.410330516"},{"key":"10.1016\/j.jns.2022.120526_bb0215","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0026-895X(25)09898-0","article-title":"Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism","volume":"45","author":"Veitch","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jns.2022.120526_bb0220","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/jnnp.64.6.799","article-title":"Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal","volume":"64","author":"Mazurek","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2022.120526_bb0225","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14740338.5.6.759","article-title":"Drug-induced parkinsonism","volume":"5","author":"Mena","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jns.2022.120526_bb0230","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2990.1999.00202.x","article-title":"Unbiased morphometrical measurements show loss of pigmented nigral neurones with aging","volume":"25","author":"Ma","year":"1999","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jns.2022.120526_bb0235","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1471-4159.1992.tb09766.x","article-title":"Aging produces a specific pattern of striatal dopamine loss. Implication for the etiology of idiopathic Parkinson\u2019s disease","volume":"58","author":"Kish","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120526_bb0240","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp.60.2.213","article-title":"Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs","volume":"60","author":"Bocola","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2022.120526_bb0245","doi-asserted-by":"crossref","unstructured":"J.Y. Hong, M.K. Sunwoo, J.S. Oh, J.S. Kim, J.H. Sohn, P.H. Lee, Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging, PLoS One doi.https:\/\/doi.org\/10.1371\/journal.pone.0157410.","DOI":"10.1371\/journal.pone.0157410"},{"key":"10.1016\/j.jns.2022.120526_bb0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2012.06.003","article-title":"[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism","volume":"139","author":"Tinazzi","year":"2012","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.jns.2022.120526_bb0255","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00002826-199510000-00004","article-title":"Effect of calcium antagonists on the dopamine system","volume":"13","author":"Mena","year":"1995","journal-title":"Clin. Neuropharmacol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:02:43Z","timestamp":1758384163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22003884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":51,"alternative-id":["S0022510X22003884"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120526","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Permanent non-progressive cinnarizine and flunarizine-induced parkinsonism: An under-recognized tardive syndrome in the elderly?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120526"}}